Loading...
NPI 1194463208 · Grapevine, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jds Labs LLC is a clinical medical laboratory provider located in Grapevine, Texas. This profile covers 18 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Jds Labs LLC |
| Address | 1220 Texan Trl Ste 205 |
| City | Grapevine |
| State | TX |
| ZIP | 76051 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | May 27, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $6.1M |
| Medicaid | $312.5K |
JDS LABS LLC appears to operate as a high-volume clinical testing entity with a clear emphasis on COVID-19 diagnostic distribution to Medicare beneficiaries; its Medicare top code K1034 has 432.7K claims and $5.2M revenue (83.2% of the provider's Medicare revenue) and the practice reports $6.1M total Medicare revenue. The dominance of a nonprescription, self‑administered COVID test code alongside multiple infectious-agent NAAT codes indicates a business model built around mass testing and specimen processing rather than a narrow specialty clinical service.
Revenue concentration is extreme for both payers: the provider’s top three Medicare codes account for 91.2% of Medicare revenue, and the top three Medicaid codes account for 96.1% of Medicaid revenue. Those precomputed shares show the provider’s financial picture is heavily dependent on a very small set of codes, which creates sensitivity to reimbursement or utilization changes for those specific services.
On the Medicare side JDS LABS is a national outlier for K1034 — the code ranks #91 of 30143 providers nationally and is labeled an "extreme outlier, far above typical national volume for this code" — indicating the provider is operating at a scale for this test that far exceeds most peers. By contrast, its other high-volume Medicare infectious-disease codes such as 87798 (11.7K claims, $396.9K revenue) and 87481 (2.9K claims, $100.1K revenue) are described as "typical, unremarkable volume," so the organization’s national competitive standing is overwhelmingly driven by the K1034 volume rather than a broad market-leading position across many codes.
The provider also bills a range of molecular/genetic tests on Medicare at much lower volumes but higher per-claim payments, including 81307 ($70.2K revenue, $656 avg paid/claim), 81317 ($68.3K revenue, $663 avg paid/claim) and 81298 ($64.8K revenue, $629 avg paid/claim). These genetic codes each rank around the mid-percentiles nationally (roughly 40–60th percentile), suggesting JDS LABS participates modestly in specialty genetic testing without showing the same outsized market share seen for its COVID self-test billing.
Medicaid activity is concentrated in COVID and respiratory testing: U0004 (2.2K claims, $172.5K revenue) accounts for 55.1% of the provider’s Medicaid revenue, 87637 (457 claims, $70.4K revenue) accounts for 22.5%, and G2023 (2.3K claims, $58K revenue) accounts for 18.5%. In-state ranks for these Medicaid codes are in the typical range (for example U0004 ranks #31 of 104 in-state and G2023 ranks #53 of 335 in-state), indicating solid participation in state COVID testing volumes but not clear market dominance within Texas.
The payer mix is heavily Medicare‑skewed: total Medicare revenue is $6.1M versus total Medicaid revenue of $312.5K, so Medicare is the principal revenue source on file. This makes the provider effectively Medicare-focused in scale, with Medicaid serving a much smaller role in absolute dollars despite similar code types being billed across both payers.
The provider’s NPI was enumerated on 2022-05-27 (~4 years ago), which indicates a relatively recent market entry yet rapid scale-up of high-volume COVID testing billing — particularly for K1034 where the provider shows unusually large national volume. Rapid accrual of hundreds of thousands of K1034 claims in a short tenure suggests an operational model optimized for mass distribution/processing of self-administered COVID tests rather than a slow-build clinical referral base.
From a risk and operational lens, JDS LABS’s revenue profile combines very high-volume, low‑avg‑paid COVID testing (e.g., K1034 at $12 avg paid/claim) with low-volume, high‑avg‑paid genetic assays (e.g., 81307 at $656 avg paid/claim), creating two distinct service lines with different margin and utilization dynamics. Given the precomputed concentration (91.2% Medicare, 96.1% Medicaid) the business is exposed to policy, reimbursement, or demand shifts that affect a handful of codes, and payers or competitors evaluating network value should treat the provider as a specialized high-volume COVID testing operator with supplementary genomic testing capacity.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
18 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 432,670 | $10 | $5.2M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 11,670 | $30 | $396.9K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 2,950 | $30 | $100.1K |
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 110 | $660 | $70.2K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 100 | $660 | $68.3K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 100 | $630 | $64.8K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 110 | $590 | $62.9K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 110 | $590 | $62.9K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 110 | $490 | $52.3K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 900 | $30 | $30.5K |
Showing 1–10 of 18
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 18 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
18 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81317 | 10 | 20 | 220 | $660 | $382.7K |
| 81298 | 10 | 20 | 220 | $630 | $362.7K |
| 81307 | 10 | 20 | 150 | $660 | $361.4K |
| 81249 | 10 | 20 | 80 | $590 | $319.2K |
| 81238 | 10 | 20 | 110 | $590 | $281.7K |
| 87798 | 33 | 300 | 790 | $30 | $265.1K |
| 81223 | 11 | 30 | 70 | $450 | $197.4K |
| K1034 | 17 | 2,490 | 450 | $10 | $117.8K |
| 81339 | 13 | 20 | 280 | $180 | $100.3K |
| 81279 | 15 | 20 | 270 | $180 | $86.8K |
Showing 1–10 of 18
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 2,210 | $80 | $172.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 460 | $150 | $70.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,320 | $30 | $58K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 340 | $20 | $7.6K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,550 | $1 | $4.6K |
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 54 | 120 | 340 | $120 | $422K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 31 | 100 | 470 | $50 | $319.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 154 | 260 | 640 | $20 | $137.2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 53 | 340 | 220 | $10 | $24.1K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 12 | 80 | 340 | $1 | $1.5K |
Other providers in the same ZIP code as Jds Labs LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Tqc, LLC | TX | Community/Behavioral Health Agency | $0 | $12.4M |
| Barry Firstenberg | TX | Hematology & Oncology Physician | $985K | $0 |
| Saira Momin | TX | MOHS-Micrographic Surgery Physician | $674.7K | $0 |
| Lonestar Ambulatory Surgical Center | TX | Ambulatory Surgical Clinic/Center | $564K | $0 |
| Raul Santos | TX | Cardiovascular Disease Physician | $471.7K | $0 |
| Nathan Graves | TX | Urology Physician | $449.7K | $0 |
| Sonal Patel | TX | Optometrist | $392.9K | $0 |
| Virginia Morgan | TX | Family Nurse Practitioner | $388.5K | $0 |
| Kevin Theleman | TX | Cardiovascular Disease Physician | $381.7K | $0 |
| Daniel Walker | TX | Dermatology Physician | $361.8K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.